StockData
GRI Bio, Inc. logo

GRI Bio, Inc. (GRI) stock

GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.35−0.05 (-3.54%)

Close on Nov 17, 2026Market cap $2.95MP/E –Yield –

GRI Bio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

GRI Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$10.42M. For fiscal 2025 it was -$10.19M. The highest annual figure on record is -$1.09M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.19M–
FY2024Dec 31, 2024-$8.61M–
FY2023Dec 31, 2023-$8.99M–
FY2022Dec 31, 2022-$1.09M–
FY2021Dec 31, 2021-$8.31M–
FY2020Dec 31, 2020-$3.71M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.45M–
Q1 FY2026Mar 31, 2026-$3.69M–
Q4 FY2025Dec 31, 2025-$2.97M–
Q3 FY2025Sep 30, 2025-$2.31M–
Q2 FY2025Jun 30, 2025-$3.17M–
Q1 FY2025Mar 31, 2025-$1.74M–
Q4 FY2024Dec 31, 2024-$2.00M–
Q3 FY2024Sep 30, 2024-$2.27M–
Q2 FY2024Jun 30, 2024-$2.14M–
Q1 FY2024Mar 31, 2024-$2.20M–
Q4 FY2023Dec 31, 2023-$5.56M–
Q3 FY2023Sep 30, 2023-$1.31M–
Q2 FY2023Jun 30, 2023-$1.54M-170.8%
Q1 FY2023Mar 31, 2023-$579.00K–
Q4 FY2022Dec 31, 2022-$844.00K–
Q3 FY2022Sep 30, 2022-$125.00K–
Q2 FY2022Jun 30, 2022$2.17M–
Q1 FY2022Mar 31, 2022-$2.29M–
Q4 FY2021Dec 31, 2021-$1.58M–
Q3 FY2021Sep 30, 2021-$1.29M–
Q2 FY2021Jun 30, 2021-$2.49M–
Q1 FY2021Mar 31, 2021-$2.95M–
Q4 FY2020Dec 31, 2020-$808.00K–
Q3 FY2020Sep 30, 2020-$1.06M–
Q2 FY2020Jun 30, 2020-$1.07M–
Q1 FY2020Mar 31, 2020-$766.00K–

More GRI Bio figures

See a number that looks wrong?